Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.

Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...

Eli Lilly's Kisunla has been approved in Japan for early symptomatic Alzheimer's disease, following its US approval in July ...

Eli Lilly's Kisunla receives Japanese approval for the treatment of early symptomatic Alzheimer's disease: Indianapolis Wednesday, September 25, 2024, 09:00 Hrs [IST] The Ministry ...

Indianapolis: Eli Lilly and Company's has announced that the Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for ...

They've gotten the green light from the FDA for some important new drugs, like Kisunla for Alzheimer's - which is now being used clinically after its July approval - and Ebglyss for eczema. But that's ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 594.50% and ...

Kisunla™ (donanemab-azbt), pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of ...

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

In U.N. Speech, Biden Says World Faces an ‘Inflection Point’ Amid Turmoil The U.N. General Assembly has begun in New York City as conflicts rage across the world. In his final U.N. speech ...

The U.S. Justice Department plans to charge the man accused of hiding with a gun at former President Donald Trump's Florida golf course with attempting to assassinate a major political candidate ...